

# TSR-011 – Licensing Deal with Amgen



LEERINK SWANN

- Exclusive W/W rights
- \$0.5MM upfront to Amgen
- Up to \$138MM in milestones to Amgen
- Tiered royalties to Amgen (mid-single digits to slightly above single digits)
- Effective until the later of
  - Last patent licensed from Amgen
  - Loss of regulatory exclusivity
  - 10<sup>th</sup> anniversary of the first commercial sale
- Deal in March 2011